Tradestie Institutional Equity Comparison Engine
QTTB vs RADX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
QTTB Overall Edge
QTTB Captures Institutional Edge (4โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Q32 Bio Inc. Common Stock (QTTB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, QTTB trades at N/M Forward P/E with 34.2% operating margin (+0.0% YoY revenue) versus RADX at N/M Forward P/E and -411.6% operating margin (-36.9% YoY). In options structure, QTTB sits in BREAKDOWN (42nd %ile IV; Dealer Gamma Walls on Pro) against RADX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
QTTB
QTTB N/M vs RADX N/M Fwd P/E
Growth & Margin Winner
QTTB
Op Margin 34.2% vs -411.6% ยท YoY +0.0% vs -36.9%
Momentum & Technical Winner
QTTB
1Y +293.4% vs -86.0% ยท 52W Pos 30% vs 0%
Options & Structure Winner
QTTB
BREAKDOWN (42nd %ile IV) vs UNCLASSIFIED (N/A IV)
QTTB
NASDAQ
Q32 Bio Inc. Common Stock
Pharmaceutical Preparations
$8.34
-1.65% 1D
Market Cap
$253.8M
1M Return
-5.23%
1Y Return
+293.4%
Forward P/E
N/M
Unified AI Score
40.8 / 100
SELL
Tech 23.0
Fund 54.0
Flow 71.0
Mom 50.0
RADX
NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap
$10.6M
1M Return
-33.64%
1Y Return
-86.04%
Forward P/E
N/M
Unified AI Score
41.1 / 100
SELL
Tech 25.0
Fund 45.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
QTTB +293.4%
RADX -86.04%
Spread: +379.75 pp (QTTB Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
QTTB TTM Op. Margin: 34.2%
RADX TTM Op. Margin: -411.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QTTB vs RADX. Trailing 12-month operating profitability (QTTB 34.2% vs RADX -411.6%) and valuation multiples (QTTB N/M vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | QTTB | RADX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $253.8M | $10.6M | Larger Scale | QTTB |
| Trailing P/E Ratio Valuation | 2.4x | N/M | Lower Multiple | QTTB |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -36.9% | Higher Growth | QTTB |
| Operating Margin (TTM) Profitability | 34.2% | -411.6% | Higher Margin | QTTB |
| Net Profit Margin Profitability | 60.0% | 0.0% | Higher Margin | QTTB |
| Return on Equity (ROE) Capital Efficiency | 24.0% | -174.7% | Higher ROE | QTTB |
| 52-Week Range Position Momentum | 30% ($2โ$24) | 0% ($1โ$16) | Stronger Trend | QTTB |
| Beta / 30D Volatility Risk Regime | 0.02ฮฒ ยท 40% Vol | 0.52ฮฒ ยท 109% Vol | Lower Realized Risk | QTTB |
| Unified Institutional Score Composite Signal | 40.8 / 100 (SELL) | 41.1 / 100 (SELL) | Higher Composite | RADX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full QTTB vs RADX Buy Guide
QTTB
BREAKDOWN
93d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
42nd %ile
IV Regime
Balanced (25thโ60th %ile)
RADX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither QTTB nor RADX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.